These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 3358989)
1. Using the maximum test statistic in the two-period crossover clinical trial. Willan AR Biometrics; 1988 Mar; 44(1):211-8. PubMed ID: 3358989 [TBL] [Abstract][Full Text] [Related]
2. Use of two-stage test statistic in the two-period crossover trials. Wang SJ; Hung HM Biometrics; 1997 Sep; 53(3):1081-91. PubMed ID: 9333341 [TBL] [Abstract][Full Text] [Related]
3. Analysis of two-period crossover design in a multicenter clinical trial. Castellana JV; Patel HI Biometrics; 1985 Dec; 41(4):969-77. PubMed ID: 3830261 [TBL] [Abstract][Full Text] [Related]
4. Carryover and the two-period crossover clinical trial. Willan AR; Pater JL Biometrics; 1986 Sep; 42(3):593-9. PubMed ID: 3567292 [TBL] [Abstract][Full Text] [Related]
5. The crossover experiment for clinical trials. Brown BW Biometrics; 1980 Mar; 36(1):69-79. PubMed ID: 7370374 [TBL] [Abstract][Full Text] [Related]
6. A Bayesian analysis of the two-period crossover design for clinical trials. Grieve AP Biometrics; 1985 Dec; 41(4):979-90. PubMed ID: 3830262 [TBL] [Abstract][Full Text] [Related]
7. Design considerations in crossover trials with a single interim analysis and serial patient entry. Cook RJ; Willan AR Biometrics; 1996 Jun; 52(2):732-9. PubMed ID: 8672709 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Curtin F; Elbourne D; Altman DG Stat Med; 2002 Aug; 21(15):2161-73. PubMed ID: 12210631 [TBL] [Abstract][Full Text] [Related]
10. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. Lathyris DN; Trikalinos TA; Ioannidis JP Int J Epidemiol; 2007 Apr; 36(2):422-30. PubMed ID: 17301102 [TBL] [Abstract][Full Text] [Related]
11. Efficacy evaluation for monotherapies in two-by-two factorial trials. Hung HM; Chi GY; O'Neill RT Biometrics; 1995 Dec; 51(4):1483-93. PubMed ID: 8589235 [TBL] [Abstract][Full Text] [Related]
12. Comparing two independent incidence rates using conditional and unconditional exact tests. Han C Pharm Stat; 2008; 7(3):195-201. PubMed ID: 17506083 [TBL] [Abstract][Full Text] [Related]
13. Design and analysis of group sequential logrank tests in maximum duration versus information trials. Kim K; Boucher H; Tsiatis AA Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714 [TBL] [Abstract][Full Text] [Related]
14. Design and analysis issues for crossover designs in phase I clinical studies. Boon PC; Roes KC J Biopharm Stat; 1999 Mar; 9(1):109-28. PubMed ID: 10091913 [TBL] [Abstract][Full Text] [Related]
15. Interim analyses for randomized clinical trials: the group sequential approach. Pocock SJ Biometrics; 1982 Mar; 38(1):153-62. PubMed ID: 7082757 [TBL] [Abstract][Full Text] [Related]
16. Paired versus two-sample design for a clinical trial of treatments with dichotomous outcome: power considerations. Wacholder S; Weinberg CR Biometrics; 1982 Sep; 38(3):801-12. PubMed ID: 7171700 [TBL] [Abstract][Full Text] [Related]
17. Three-period crossover designs for two treatments. Ebbutt AF Biometrics; 1984 Mar; 40(1):219-24. PubMed ID: 6733230 [TBL] [Abstract][Full Text] [Related]
18. An alternative analysis for crossover studies that accounts for between-group disparities in drug response. Cleophas TJ Eur J Clin Chem Clin Biochem; 1997 Oct; 35(10):775-9. PubMed ID: 9368796 [TBL] [Abstract][Full Text] [Related]
19. Angina clinical trial methodology. Ford I Postgrad Med J; 1991; 67 Suppl 3():S2-8. PubMed ID: 1758828 [TBL] [Abstract][Full Text] [Related]
20. Applications of extensions of bivariate rank sum statistics to the crossover design to compare two treatments through four sequence groups. Kawaguchi A; Koch GG; Ramaswamy R Biometrics; 2009 Sep; 65(3):979-88. PubMed ID: 19173698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]